OxyMem Ltd

OxyMem Ltd

OxyMem solves energy intensive wastewater treatment with an innovative ‘Drop in’ solution for wastewater aeration, the Membrane Aerated Biofilm Reactor (MABR). OxyMem MABR complements existing treatment systems and delivers up to 50% additional biological capacity in an existing aeration or alternatively enables you to replace a legacy system. Conventional wastewater treatment consumes 2-3% of a nation’s electricity production. This is due a 100 years reliance on bubble diffusion for conventional treatment plants which will typically suffer energy losses of 65-70% in the process because of the oxygen transfer limitations in the process. OxyMem does not have any such limitations. OxyMem was the first to commercialise Membrane Aerated Biofilm Reactor (MABR) products, having done so in early 2014. To date, OxyMem has successfully installed over twenty systems for clients located in various countries around the world.

Company details

Unit F, Moydrum Business Park , Athlone , Co. Westmeath N37 DR79 Ireland

More Office Locations Locations Served

Business Type:
Industry Type:
Water and Wastewater - Water Aeration and Mixing
Market Focus:
Globally (various continents)
Year Founded:

OxyMem uses hollow fibre gas permeable membranes to support a fixed film ecosystem for the biology which allows for direct delivery of oxygen to the micro-organisms. OxyMem can achieve 95% oxygen transfer rates which results in superior energy performance (75% saving), lower sludge production (50% less sludge), along with impressive process resilience.

Our Awards
OxyMem have been fortunate to have won numerous awards over the past few years. The following represent some of the key ones:

OxyMem was the first to commercialise Membrane Aerated Biofilm Reactor (MABR) products, having done so in early 2014. To date, OxyMem has successfully installed over twenty systems for clients located in various countries around the world.

In October 2015, a competitor of OxyMem alleged that OxyMem’s MABR products would infringe certain of the competitor’s U.S. patents if those products were sold or offered for sale in the U.S. OxyMem reviewed the patents and advised the competitor that there was no merit to such allegation. Notwithstanding this, the competitor sent a cease-and-desist letter on February 12, 2016 during the period when OxyMem was in the process of closing a major funding round. Unfortunately, due to the expenses typically involved with disputes, at that time OxyMem wasn’t in a position to resist a legal threat or challenge from a large competitor. Consequently, in order to avoid disrupting the financing and to enable us to carry out a further legal review, OxyMem stepped back from the U.S. Today, OxyMem has no operations in the U.S. nor does it have plans to operate in the U.S. As previously reported, the financing round closed in [March 2016], six weeks following the cease-and-desist letter.

Since that time, OxyMem has conducted a further review of the relevant patents, and we continue to assert that our MABR products would not infringe any valid claims of the U.S. patents identified by the competitor.

In light of the foregoing and because all of its customers are located outside the U.S., Oxymem will be pleased to offer the following assurances to its customers pursuant to the written agreement that Oxymem may enter into with its customers:

  1. FTO and IP indemnities;
  2. 10-year product guarantees for municipal applications and 5-year product guarantees for industrial applications;
  3. Performance & Process guarantees based on customer KPI’s; and
  4. Best performance MABR at lowest cost

In order to help OxyMem correct any misleading or inaccurate statements, OxyMem respectfully requests that you please make us aware of any allegations from third parties that state OxyMem is not able to serve a particular market. We appreciate your support in this.


In 1914, around the same time Henry Ford was constructing his first assembly line for the model T, the Conventional Activated Sludge (CAS) process was developed. Since then the treatment of wastewater has been using bubble aeration to treat wastewater.  This is a highly wasteful process as 60-70% of the energy is lost to atmosphere with bubble aeration which has led to major financial and operational challenges for operators. On a global scale, this process will typically consume 2-3% of the total electricity production of a nation. Operators have had to endure high OPEX costs driven by; high energy demands, high cost of skilled labour, and significant sludge disposal costs. To date there has been a lack of a commercially viable alternatives in aeration technology space…until now.


OxyMem MABR does not use bubbles for oxygen delivery and therefore has multiple technical and commercial advantages for operators. We utilise gas permeable membranes to deliver oxygen directly to the micro-organisms that break down the carbon and nitrogen based pollutants. OxyMem achieves superior performance, on a smaller footprint, with less sludge production, less operator hours, and achieves energy savings in excess of 75%. In this way, OxyMem provides aeration through the most efficient delivery system available on the market today, the Membrane Aerated Biofilm Reactor (MABR).


In the late 1990’s the researchers of OxyMem began with the objective of developing a more efficient way of treating wastewater.  Embedded within the school of Chemical and Bioprocess Engineering, University College Dublin (UCD) they built on the 1970’s concept of using gas permeable membranes for the aeration of wastewater.  By late 2013 OxyMem Limited was successfully spun out of the University and began selling commercial MABRs in mid 2014. Since then, the OxyMem has delivered multiple systems at varying scales to clients like: Severn Trent Water (UK), South Dublin CC (Ireland), Enisca (NI), Xylem (Sweden), Agbar (Spain), Dow Water (Brazil), & Kurita (Japan). OxyMem is currently offering it’s 4th Generation ‘drop in’ MABR and is busy working on Generation 5.


OxyMem invented a system that provides a unique and convenient way of measuring biofilm thickness, utilising this method to detect excessive biofilm growth allows for automatic removal of excessive biofilm by air scouring. University College Dublin filed a PCT application for this invention on the 28th November 2008 (European Patent Application EP08105882.8 / United States Patent Application No. 13/131,605 PL Ref: P10249USPC). The patent was issued by the EPO in January 2013 and on April 15 2014 in USA.  Since 2013 OxyMem have filed a number of ground breaking PCT applications in the MABR field. We look forward to sharing these with you in the near future. For now, we continue to ensure we remain at the forefront of wastewater treatment innovation.

Our Mission is to make MABR the First Choice for Aerobic Wastewater Treatment

Conventional Activated Sludge (CAS) – Wastes 70% of the energy delivering oxygen

Conventional wastewater treatment consumes between 2-3% of a nation’s total electricity production. This is due to a 100 year reliance on bubble diffusion for conventional secondary treatment which will typically suffer energy losses of 65-70% in the process because of the oxygen transfer limitations in the bubble aeration process.


The Membrane Aerated Biofilm Reactor (MABR) does not have any such limitations as it does not rely on bubbles to deliver oxygen to the biology that breaks down the wastewater. This makes MABR 7 times more energy efficient than Conventional Activated Sludge (CAS) and 10X more efficient than Moving Bed Bioflm Reactors (MBBR).

At OxyMem, we are providing products and services which continue to challenge the inefficiencies of the past 100 years. In doing so we enable our customers to build and operate energy efficient biological wastewater treatment plants and allowing them to get closer to energy neutral wastewater treatment goals.


MABR Module (Gen 4)

OxyMem is recognised as developing the world’s first commercially available Membrane Aerated Biofilm Reactor (MABR). A leading edge technology for the wastewater treatment market.

We are committed to maintaining the level of technical excellence that first allowed us to deliver the MABR to the market in 2014. We will continue to work with our partners and customers to advance innovation around this smart aeration solution so as to remain the recognised pioneer of Membrane Aerated Biofilm Reactor.

  • Cost Leadership
  • Quality & Service excellence
  • Exceptional Product Performance
  • Long Term, Value-Added Relationships with our Customers and Strategic Partners
  • Continuous Research, Development and Innovation to Meet the Needs of our Customers and the Marketplace
  • Best Performance at Lowest Cost